// App-Quantinova.ai

2622 : An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Researchers

Presenter

  • Kenneth W. Wood

Principal Investigators

  • James Geib

  • Eric Wu

  • Jason Berlin

  • Irena Webster

  • Kenneth I. Ataga

  • Jo Howard

  • Jeremie H. Estepp

  • Marilyn J. Telen

  • Julie Brevard

Medical Centers

  • FORMA Therapeutics, Inc., Watertown, MA

  • The University of Tennessee Health Science Center, Memphis, TN

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Duke Univ. Med. Ctr., Durham, NC

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Sickle cell anemia

  • Chronic obstructive pulmonary disease

  • Renal insufficiency

  • Stroke

Biomarkers

  • Pyruvate

  • Stearoyl-CoA desaturase

  • Red Blood Cells

  • Volatile organic compounds

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Adaptive

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved